Compare Quest Diagnostics Inc (DGX) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Tesla, Inc. — how do they compare? Quest Diagnostics Inc trades at $237.01 (market cap $26.21B), while Tesla, Inc. trades at $325 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 50× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| DGX | TSLA | |
|---|---|---|
Market Cap | $26.21B | $1.31T |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $489.88 |
52-Week Low | $173.49 | $298.16 |
Enterprise Value | $31.97B | $1.29T |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Tesla (TSLA) trades at $330.87, up 0.7% on the day, with a bearish technical signal from moving averages and a mixed fundamental picture. The stock shows high valuation multiples (P/E 308.16, P/S 11.36) amid declining profitability, with net income margin falling to 3.67% in 2025 from 15.49% in 2023. Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV model, but Q2 2026 earnings missed expectations.
Outlook remains polarized: analyst consensus price target of $393.87 suggests 19% upside, but high valuation and margin compression pose risks. Key catalysts include autonomy advancements and energy/robotics growth, while competition and execution challenges weigh on sentiment. The stock's trajectory hinges on delivering AI-driven revenue streams beyond automotive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
